Prof. Marie Scully University College Hospital, London 22nd December 2020 COVID 19 vaccination and TTP The COVID 19 vaccine is being rolled out and over the next few weeks/months everyone will be called. The majority of patients should have it when offered-currently there are 2 doses. There are a few considerations for patients with…
Update 16th December 2020 The Final Guidance has now been published on the NICE website: www.nice.org.uk/guidance/TA667 TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP Nice have today published the following decision: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for…
Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill-defined…
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombomicroangiopathy caused by deficiency of ADAMTS13. Acute neurological involvement is well described, but its long‐term impact requires evaluation. One‐hundred thirty‐one patients, following an acute TTP event, with severe headache or neurological symptoms had a cerebral MRI…
Prof. Marie Scully University College Hospital, London 15th March 2020 As you all know, COVID19 has been heightened to a pandemic. There are continuous updates from Government and senior scientists and many changes are required within the NHS at this time. There may be regional variations but there have had to be significant and…
Professor Marie Scully We are privileged and honoured to have Professor Marie Scully, as our Patron. Professor Scully is an inspirational woman, and Consultant Haematologist at University College London. Prof. Scully has been an unwavering champion of TTPNetwork for many years and her invaluable support has made a huge impact on raising awareness of our…